SELECT PUBLICATIONS
Cassidy J et al. XELOX vs FOLFOX4: Efficacy results from XELOX-1/NO16966,
a randomized phase III trial in first-line metastatic colorectal cancer (MCRC).
Gastrointestinal Cancers Symposium 2007;Abstract 270.
De Gramont A et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy
results of the MOSAIC trial, including survival, with a median follow-up of six years.
Proc ASCO 2007a;Abstract 4007.
De Gramont A et al. Reintroduction of oxaliplatin is associated with improved survival in
advanced colorectal cancer. J Clin Oncol 2007b;25(22):3224-9. Abstract
De Gramont A et al. Oxaliplatin/5-FU/LV in the adjuvant treatment of stage II and
stage III colon cancer: Efficacy results with a median follow-up of 4 years. Proc ASCO
2005;Abstract 3501.
De Gramont A et al. OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in
patients with advanced colorectal cancer. Proc ASCO 2004;Abstract 3525.
De Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized mosaic trial. Proc ASCO 2003;Abstract 1015.
Grothey A et al. Association between exposure to bevacizumab (BV) beyond first progression (BBP) and overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC): Results from a large observational study (BRiTE). Proc ASCO 2007;Abstract 4036.
Maindrault-Goebel F et al. Final results of OPTIMOX2, a large randomized phase II
study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX
in patients with metastatic colorectal cancer (MRC): A GERCOR study. Proc ASCO
2007;Abstract 4013.
Maindrault-Goebel F et al. OPTIMOX2, a large randomized phase II study of maintenance therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with metastatic colorectal cancer (MRC). A GERCOR study. Proc ASCO 2006;Abstract 3504.
Saltz LB et al. Bevacizumab (Bev) in combination with XELOX or FOLFOX4: Efficacy results from XELOX-1/NO16966, a randomized phase III trial in the first-line treatment of
metastatic colorectal cancer (MCRC). Gastrointestinal Cancers Symposium 2007;Abstract 238.
Sargent DJ et al. Disease-free survival versus overall survival as a primary end point
for adjuvant colon cancer studies: Individual patient data from 20,898 patients on 18
randomized trials. J Clin Oncol 2005;23(34):8664-70. Abstract
Tournigand C et al. Modified (m)Folfox7/bevacizumab (B) or modified (m)Xelox/bevacizumab with or without erlotinib (E) in first-line metastatic colorectal
cancer (MCRC): Results of the feasibility phase of the DREAM-OPTIMOX3 study
(GERCOR). Proc ASCO 2007;Abstract 4097.
Tournigand C et al. OPTIMOX1: A randomized study of FOLFOX4 or FOLFOX7 with
oxaliplatin in a stop-and-go fashion in advanced colorectal cancer — A GERCOR
study. J Clin Oncol 2006;24(3):394-400. Abstract
